MA50943A - Anticorps anti-liv1 humanisés pour le traitement du cancer du sein - Google Patents
Anticorps anti-liv1 humanisés pour le traitement du cancer du seinInfo
- Publication number
- MA50943A MA50943A MA050943A MA50943A MA50943A MA 50943 A MA50943 A MA 50943A MA 050943 A MA050943 A MA 050943A MA 50943 A MA50943 A MA 50943A MA 50943 A MA50943 A MA 50943A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- breast cancer
- humanized anti
- liv1
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593660P | 2017-12-01 | 2017-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50943A true MA50943A (fr) | 2020-10-07 |
Family
ID=64746653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050943A MA50943A (fr) | 2017-12-01 | 2018-11-30 | Anticorps anti-liv1 humanisés pour le traitement du cancer du sein |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200283540A1 (https=) |
| EP (1) | EP3717518A1 (https=) |
| JP (2) | JP2021505540A (https=) |
| KR (1) | KR20200090838A (https=) |
| CN (1) | CN111757892A (https=) |
| AU (1) | AU2018375182A1 (https=) |
| BR (1) | BR112020010937A2 (https=) |
| CA (1) | CA3084495A1 (https=) |
| EA (1) | EA202091360A1 (https=) |
| IL (1) | IL274766A (https=) |
| MA (1) | MA50943A (https=) |
| MX (1) | MX2020005640A (https=) |
| SG (1) | SG11202004751TA (https=) |
| WO (1) | WO2019109007A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6105481B2 (ja) | 2010-12-06 | 2017-03-29 | シアトル ジェネティクス，インコーポレーテッド | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| MA45324A (fr) * | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| GB201908208D0 (en) * | 2019-06-10 | 2019-07-24 | Univ College Cardiff Consultants Ltd | An anti-mitotic agent |
| BR112022001045A2 (pt) * | 2019-07-22 | 2022-07-19 | Seagen Inc | Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit |
| BR112022011268A2 (pt) * | 2019-12-09 | 2022-09-06 | Seagen Inc | Terapia de combinação com antagonista de liv1-adc e pd1 |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CN119317646A (zh) * | 2022-06-16 | 2025-01-14 | 山东博安生物技术股份有限公司 | 抗liv-1抗体及其药物偶联物 |
| AU2024218701A1 (en) | 2023-02-07 | 2025-08-21 | LaNova Medicines Limited | Antibodies targeting liv-1 and uses thereof |
| JP2026509871A (ja) * | 2023-03-15 | 2026-03-25 | 浙江博鋭生物製薬有限公司 | 抗ｌｉｖ－１抗体及び抗ｌｉｖ－１抗体薬物複合体並びにその薬物的使用 |
| WO2025146137A1 (zh) * | 2024-01-05 | 2025-07-10 | 海南先声再明医药股份有限公司 | 抗liv-1抗体药物偶联物及其用途 |
| CN120040587B (zh) * | 2025-04-27 | 2025-08-08 | 上海宏成药业有限公司 | 抗liv-1抗体或其抗原结合片段及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| WO2004067564A2 (en) | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物 |
| US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| CN101622273A (zh) * | 2006-04-13 | 2010-01-06 | 诺瓦提斯疫苗和诊断公司 | 治疗、诊断或检测与liv-1过量表达相关的癌症的方法 |
| RU2476441C2 (ru) | 2007-10-19 | 2013-02-27 | Сиэтл Дженетикс, Инк. | Cd19-связывающие средства и их применение |
| JP6105481B2 (ja) | 2010-12-06 | 2017-03-29 | シアトル ジェネティクス，インコーポレーテッド | Ｌｉｖ−１に対するヒト化抗体および癌治療のためのその使用 |
| CA2873111A1 (en) * | 2012-05-11 | 2013-11-14 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics |
| US9492566B2 (en) * | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| WO2015175533A2 (en) * | 2014-05-13 | 2015-11-19 | Immunogen, Inc. | Anti-cd37 immunoconjugate dosing regimens |
| MA45324A (fr) * | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
-
2018
- 2018-11-30 MA MA050943A patent/MA50943A/fr unknown
- 2018-11-30 SG SG11202004751TA patent/SG11202004751TA/en unknown
- 2018-11-30 BR BR112020010937-1A patent/BR112020010937A2/pt not_active IP Right Cessation
- 2018-11-30 JP JP2020529281A patent/JP2021505540A/ja active Pending
- 2018-11-30 CA CA3084495A patent/CA3084495A1/en active Pending
- 2018-11-30 AU AU2018375182A patent/AU2018375182A1/en not_active Abandoned
- 2018-11-30 CN CN201880077514.3A patent/CN111757892A/zh active Pending
- 2018-11-30 US US16/768,020 patent/US20200283540A1/en not_active Abandoned
- 2018-11-30 WO PCT/US2018/063425 patent/WO2019109007A1/en not_active Ceased
- 2018-11-30 KR KR1020207017651A patent/KR20200090838A/ko not_active Abandoned
- 2018-11-30 EP EP18822563.5A patent/EP3717518A1/en not_active Withdrawn
- 2018-11-30 EA EA202091360A patent/EA202091360A1/ru unknown
- 2018-11-30 MX MX2020005640A patent/MX2020005640A/es unknown
-
2020
- 2020-05-19 IL IL274766A patent/IL274766A/en unknown
-
2023
- 2023-03-07 US US18/179,560 patent/US20240076402A1/en not_active Abandoned
- 2023-10-06 JP JP2023173950A patent/JP2024001187A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018375182A1 (en) | 2020-06-11 |
| JP2024001187A (ja) | 2024-01-09 |
| SG11202004751TA (en) | 2020-06-29 |
| KR20200090838A (ko) | 2020-07-29 |
| BR112020010937A2 (pt) | 2020-11-17 |
| US20240076402A1 (en) | 2024-03-07 |
| CA3084495A1 (en) | 2019-06-06 |
| WO2019109007A1 (en) | 2019-06-06 |
| IL274766A (en) | 2020-07-30 |
| CN111757892A (zh) | 2020-10-09 |
| MX2020005640A (es) | 2020-08-20 |
| EP3717518A1 (en) | 2020-10-07 |
| EA202091360A1 (ru) | 2020-08-24 |
| US20200283540A1 (en) | 2020-09-10 |
| JP2021505540A (ja) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50943A (fr) | Anticorps anti-liv1 humanisés pour le traitement du cancer du sein | |
| FR25C1001I2 (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| EP3494142A4 (en) | ANTI-SIGLEC-7 ANTIBODIES FOR TREATING CANCER | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
| EP3431105A4 (en) | MEDICAL COMPOSITION FOR THE TREATMENT OF CANCER | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| EP3452060A4 (en) | Combination therapy for cancer treatment | |
| EP3641829A4 (en) | INTERFERON PRODRUG FOR TREATMENT OF CANCER | |
| EP3400010A4 (en) | ANTI-HER2 COMBINATIONS FOR THE TREATMENT OF TUMORS | |
| EP3630196A4 (en) | COMBINATION THERAPIES FOR TREATMENT OF CANCER | |
| EP3474854A4 (en) | CANCER TREATMENT COMBINATIONS | |
| EP3389645A4 (en) | COMBINATIONS FOR TREATING CANCER | |
| EP3359255A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | |
| EP3490561A4 (en) | COMBINATIONS FOR TREATING CANCER | |
| EP3383497A4 (en) | NOVEL ANTIBODIES FOR THE TREATMENT OF CANCER DISEASES | |
| EP3386522A4 (en) | Compositions and methods for treating HER2-positive metastatic breast cancer | |
| EP3541417A4 (en) | Combination immunotherapies for treatment of cancer | |
| EP3443962A4 (en) | Quinoline derivative for the treatment of gastric cancer | |
| EP3503887A4 (en) | COMBINATIONS FOR TREATING CANCER | |
| EP3793544A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| MA47776A (fr) | Polythérapies pour le traitement du cancer du sein |